Scalper1 News
Akorn (AKRX) late Friday said it would have to restate its 2014 financials, estimating that it overstated revenue and pre-tax income from continuing operations by $20 million to $35 million. Akorn shares fell 14.4% to 47.28 in after-hours action. Akorn said the “errors related to the understatementments of rebates and other sales allowances,” mostly from companies and products acquired last year. The drugmaker also named Terry Allison to its board Scalper1 News
Scalper1 News